Clinical trials: End of Life
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Cardiovascular Events
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood…
- Trial name
- APOLLO (NCT01259297)
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ)
- Where
- 185 sites in United States, Argentina and 16 more
- Volunteers
- 2,336 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma
Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?
To determine the impact of OrCam over 1 month on health-related quality of life (HRQoL) in subjects with advanced glaucoma using the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25).
- Trial name
- NCT02526680
- Testing
- OrCam
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wills Eye
Mucopolysaccharidosis II, MPS II
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
The purpose of the study is to evaluate the safety, tolerability and effect on leukocyte and plasma Iduronate 2-Sulfatase (IDS) enzyme activity of ascending doses of SB-913.
- Trial name
- NCT03041324
- Testing
- SB-913
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Sangamo Therapeutics
Myocardial Infarction
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart…
- Trial name
- NCT04509674
- Testing
- Empagliflozin
- Where
- 439 sites in United States, Argentina and 20 more
- Volunteers
- 6,522 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer, Cancer
Bintrafusp Alfa Program Rollover Study
This study is designed to provide continuous access to treatment with bintrafusp alfa for eligible participants from ongoing bintrafusp alfa parent studies (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706…
- Trial name
- NCT05061823
- Testing
- Bintrafusp alfa
- Where
- 21 sites in United States, Belgium and 10 more
- Volunteers
- 22 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Hodgkin Lymphoma
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth).
- Trial name
- NCT05508867
- Testing
- favezelimab/pembrolizumab, bendamustine, gemcitabine
- Where
- 105 sites in United States, Argentina and 18 more
- Volunteers
- 203 people
- Sponsor
- Merck Sharp & Dohme LLC
Sudden Cardiac Arrest
Educational Videos to Improve Patient Decision Making and Race Disparities in Implantable Cardioverter Defibrillator Use
The investigators will examine whether an educational video increases patient knowledge about heart failure and the risk of sudden cardiac arrest and leads to greater satisfaction with information provided as compared to usual…
- Trial name
- VIVID-01 (NCT00918125)
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Duke University
Lactation Suppressed
Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss
Breast pain following second-trimester abortion is common. Breast engorgement and milk leakage following second-trimester perinatal loss and abortion can cause both physical pain and emotional distress.
- Trial name
- eLISTA (NCT06029673)
- Testing
- Cabergoline 1 MG
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Stanford University
Respiratory Syncytial Virus Prevention
A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
The purpose of this study is to demonstrate non-inferiority in terms of humoral immune responses of Ad26.RSV.preF-based study vaccine lots representative of different aged vaccine in comparison to a non-aged Ad26.RSV.preF-based…
- Trial name
- NCT05101486
- Testing
- Ad26.RSV.PreF-based Vaccine
- Where
- 13 sites in United States
- Volunteers
- 755 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Solid Tumors, Lymphoma
Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
The purpose of this study is to identify a maximum tolerated dose (MTD) or maximum administered dose (MAD) of ulevostinag alone and of ulevostinag in combination with pembrolizumab in participants with advanced/metastatic solid…
- Trial name
- NCT03010176
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 156 people
- Sponsor
- Merck Sharp & Dohme LLC
Stable Angina
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
- Trial name
- RESIST (NCT01103440)
- Testing
- Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Atrial Fibrillation, Atrial Flutter
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).
- Trial name
- ATHENA (NCT00174785)
- Testing
- dronedarone (SR33589)
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 4,628 people
- Sponsor
- Sanofi
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal…
- Trial name
- NCT03221426
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 171 sites in United States, Belgium and 22 more
- Volunteers
- 1,007 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04303169
- Testing
- Pembrolizumab, Vibostolimab, Gebasaxturev
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Transplantation, Kidney Transplantation
Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
We hypothesize that delayed graft function and ITBS events may be related to small blood clots (microthrombi) that collect in the kidneys and liver after cardiac death.
- Trial name
- NCT01197573
- Testing
- rTPA Treatment, No TPA Treatment
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- The Cleveland Clinic
Neoplasm Metastasis
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
The purpose of this study is to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies who receive gebasaxturev (V937) in combination with pembrolizumab (MK-3475).
- Trial name
- NCT04521621
- Testing
- Gebasaxturev, Pembrolizumab
- Where
- 29 sites in United States, Canada and 12 more
- Volunteers
- 76 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Anemia
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in…
- Conditions
- Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction
- Trial name
- NCT00358215
- Testing
- Darbepoetin alfa
- Where
- 754 sites in United States, Argentina and 34 more
- Volunteers
- 2,278 people
- Sponsor
- Amgen
Heart Failure
ASIAN HF Registry, A Prospective Observational Study
The ASIAN HF Registry is the first prospective multinational Asian registry of patients with symptomatic HF (stage C) including both HFrEF (ejection fraction <40%) and HFpEF (ejection fraction ≥50%), with the broad purpose of…
- Trial name
- ASIANHF (NCT01633398)
- Testing
- Saliva Genetic testing
- Where
- 11 sites in China, Hong Kong and 9 more
- Volunteers
- 6,329 people
- Sponsor
- Carolyn Lam